Positive interaction of the novel beta2-agonist carmoterol and tiotropium bromide in the control of airway changes induced by different challenges in guinea-pigs.
This study evaluated the bronchodilating activity of the beta(2)-agonist carmoterol and the muscarinic M(3)-antagonist tiotropium, given intratracheally alone or in combination in anaesthetized artificially ventilated normal and actively sensitized guinea-pigs. Carmoterol (0.3-100pmol) and tiotropium (10-1000pmol) were superfused (0.01ml/min) for 5min before challenges with acetylcholine (20mug/kg i.v.), histamine (10mug/kg i.v.) or ovalbumin (5mg/kg i.v.). Both compounds given alone were markedly active against all the challenges. Tiotropium resulted more effective towards cholinergic challenge and carmoterol was very potent against histamine and ovalbumin-induced reaction, being effective already at 1pmol. In the presence of tiotropium, the bronchodilating activity of carmoterol was significantly augmented. The ED(50) value of carmoterol on the acetylcholine challenge was reduced by about 10 and 28 times (0.1 and 0.3pmol of tiotropium), that on the histamine one by 4.5 and 13 times (1 and 3pmol of tiotropium) and that on the ovalbumin-induced one by 8 and 25 times (10 and 30pmol of tiotropium). A positive interaction was also evident when other parameters were evaluated. The histamine-induced release of thromboxane B(2) was markedly reduced (56%, P<0.001) by combining completely ineffective doses of the two drugs (0.3 and 3pmol for carmoterol and tiotropium, respectively). In ovalbumin-challenged animals the time to death, amounting in control animals to 7.2+/-0.9min, was dose-dependently prolonged up to achieve complete protection from death with combination of 1 and 30pmol of carmoterol and tiotropium, respectively. The favorable interaction between carmoterol and tiotropium can represent a good option in the control of bronchopulmonary diseases marked by an increase of airway resistances.
Rossoni
Giuseppe
G
Department of Pharmacological Sciences, University of Milan, Milan, Italy. giuseppe.rossoni@unimi.it
Manfredi
Barbara
B
Razzetti
Roberta
R
Civelli
Maurizio
M
Berti
Ferruccio
F
D000109:Acetylcholine / Q000008:administration & dosage / Q000633:toxicity; D058666:Adrenergic beta-2 Receptor Agonists; D000402:Airway Obstruction / Q000139:chemically induced / Q000378:metabolism / Q000517:prevention & control*; D000403:Airway Resistance / Q000187:drug effects; D000662:Amphetamines / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D016084:Bronchoconstriction / Q000187:drug effects; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006168:Guinea Pigs; D006632:Histamine / Q000008:administration & dosage / Q000633:toxicity; D006912:Hydroxyquinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D007279:Injections, Subcutaneous; D008297:Male; D010047:Ovalbumin / Q000008:administration & dosage / Q000276:immunology / Q000633:toxicity; D015363:Quinolones / Q000008:administration & dosage / Q000627:therapeutic use*; D012602:Scopolamine Derivatives / Q000008:administration & dosage / Q000627:therapeutic use*; D016019:Survival Analysis; D013929:Thromboxane B2 / Q000378:metabolism; D000069447:Tiotropium Bromide; D016896:Treatment Outcome
D058666:Adrenergic beta-2 Receptor Agonists; D000662:Amphetamines; D001993:Bronchodilator Agents; D006912:Hydroxyquinolines; D015363:Quinolones; D012602:Scopolamine Derivatives; D013929:Thromboxane B2; D006632:Histamine; D010047:Ovalbumin; C074413:carmoterol; D000109:Acetylcholine; D000069447:Tiotropium Bromide